COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Doppler or Amniocentesis to Predict Fetal Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00295516
Recruitment Status : Completed
First Posted : February 23, 2006
Last Update Posted : May 24, 2006
The Physicians' Services Incorporated Foundation
Stichting Oranjekliniek, The Netherlands
Information provided by:
University of Toronto

Brief Summary:

In pregnancies complicated by Rhesus disease, the mother has developed antibodies which cross the placenta and can cause anemia and death of the fetus. When the anemia is detected on time, the fetus can be saved by giving it blood transfusions during the pregnancy.

The standard test to predict whether the fetus needs a blood transfusion is examination of the amniotic fluid. To obtain this fluid a needle has to be inserted in the womb, which has a risk of preterm delivery, infection, and making the disease worse. This is called amniocentesis.

A new safe test, using Doppler ultrasound, has been developed to possibly replace the amniocentesis.

The aim of this study is to compare the new Doppler test with the standard amniocentesis. If the Doppler test is at least as good, this safe test may replace the amniocentesis in the management of pregnancies with Rhesus disease.

Condition or disease Intervention/treatment Phase
Rh Isoimmunization Procedure: Fetal Middle Cerebral Artery Doppler measurement Phase 3

Detailed Description:

In pregnancies complicated by red cell alloimmunization, the fetus may suffer from chronic progressive hemolytic anemia. Severe fetal anemia leading to hydrops and fetal demise can occur as early as 17 weeks' gestation, while in other pregnancies the only manifestation of the disease is neonatal hyperbilirubinemia. The standard of care in the management of these pregnancies is to select patients at risk of fetal anemia using information about their obstetric history, and serial maternal serum antibody measurements. The selected patients are followed closely, usually in referral centers with a special interest and expertise in managing this now relatively rare disease. Ultrasound evaluation of fetal condition, with emphasis on signs of fetal hydrops, is performed regularly. In addition, serial amniocentesis is done to assess amniotic fluid bilirubin (deltaOD450) values. This spectrophotometric method estimates the level of bilirubin in the amniotic fluid, which correlates with the severity of the hemolytic process.

Although this diagnostic test, introduced by Liley in 1961, has served fetal medicine specialists well for almost 40 years, the invasive nature of the method is considered a serious disadvantage. Furthermore, its reliability has been questioned, especially when used in the second trimester. In the past decade, noninvasive alternative methods to predict the degree of fetal anemia have been developed.

The most promising of these new diagnostic tests is Doppler measurement of fetal blood flow velocities. Fetal blood flow velocity has been shown to correlate linearly with the degree of anemia. Recently, middle cerebral artery (MCA) peak flow velocity measurements have been reported to reliably predict presence or absence of fetal anemia.

The aim of this study is to compare the performance of this new noninvasive diagnostic test with the standard test, amniocentesis for amniotic fluid deltaOD450 values. In an international multicenter setting, a large cohort of consecutive Rh-alloimmunized pregnancies will be studied prospectively. Both diagnostic tests will be performed simultaneously in all patients, and compared with the "gold standard", fetal blood sampling (FBS) to assess the actual hemoglobin concentration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 157 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Minimally Invasive Management of Rh Alloimmunization: Can Amniotic Fluid DeltaOD450 Measurements Be Replaced by Doppler Studies?
Study Start Date : October 2000
Study Completion Date : August 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Primary Outcome Measures :
  1. Sensitivity Middle Cerebral Artery (MCA) peak velocity Doppler measurement and amniotic fluid deltaOD450 measurements, to predict fetal anemia requiring transfusion.
  2. Specificity of Middle Cerebral Artery (MCA) peak velocity Doppler measurement and amniotic fluid deltaOD450 measurements, to predict fetal anemia requiring transfusion.

Secondary Outcome Measures :
  1. Comparison of the sensitivity and specificity of the original, linearly extended Liley chart with the Queenan (1993) chart, by plotting the deltaOD450 results found in our study in both charts.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pregnant women with red cell alloimmunization associated with a risk of fetal anemia (D, E, c or Duffy (Fya )antibodies, alone or in combination with other antibodies)
  • Gestational age between 12 and 34 weeks at study entry, viable fetus and accurate dating
  • Maternal serum test-result, above the threshold at which the fetus is considered to be at risk of developing hemolytic anemia and thus a potential candidate for invasive testing.

Exclusion Criteria:

  • Presence of Kell-antibodies
  • Presence of fetal hydrops at first ultrasonographic examination
  • Major fetal congenital or chromosomal anomalies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00295516

Layout table for location information
Canada, Ontario
Mt. Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Sponsors and Collaborators
University of Toronto
The Physicians' Services Incorporated Foundation
Stichting Oranjekliniek, The Netherlands
Layout table for investigator information
Principal Investigator: Dick Oepkes, MD, PhD Leiden University Medical Centre, The Netherlands
Principal Investigator: Gareth P Seaward, MB, BCh, MSc Mt.Sinai Hospital, University of Toronto, Canada
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00295516    
Other Study ID Numbers: MSH-REB 01-0266-U
PSI Grant Number:01-13
First Posted: February 23, 2006    Key Record Dates
Last Update Posted: May 24, 2006
Last Verified: February 2006
Keywords provided by University of Toronto:
Red Cell Alloimmunization
Fetal Hemolytic Anemia
Erythroblastosis fetalis